Labarai
Sabuwar Maganin Halitta Ya Samu Nasara Wajen Magance Cututtukan Sickle Cell da Thalassemia
A wani yanayi na asibiti na farko, wani majiyyaci mai shekaru 21 ya yi nasarar shawo kan ƙalubalen thalassemia ta hanyar amfani da maganin kwayoyin halitta mai ci gaba wanda aka yi da CRISPR. Wannan sabuwar hanyar tana nuna babban ci gaba a cikin maganin cututtukan jini masu tsanani kamar cutar sikila (SCD) da thalassemia.
ASH 2024: Ƙungiyar Lu Daopei Ta Nuna Nasarorin Bincike 13 a fannin Ilimin Jini
A taron ASH na 2024 mai zuwa, ƙungiyar likitocin Asibitin Lu Daopei za ta gabatar da sabbin bincike guda 13, waɗanda suka nuna ci gaba a fannin ilimin jini da kuma yuwuwar maganin CAR-T, tare da sake jaddada alƙawarinsu na inganta sakamakon marasa lafiya.
Cin Nasara a Lymphoma tare da Maganin CAR-T Biyu
Bayan ta yi fama da cutar sankarar fata tsawon shekaru uku, wata mata mai shekaru 61 ta sami cikakkiyar sassauci ta hanyar amfani da sabuwar hanyar magance cutar sankarar fata mai suna "CAR-T" a BIOOCUS, wadda ke nuna yiwuwar maganin cutar kansa mai ci gaba da canza rayuwa.
Gyaran Halittar Halitta: Ci gaba a Fasahar CRISPR/Cas a Aikace-aikacen Kiwon Lafiya
Ci gaban da aka samu kwanan nan a fasahar CRISPR/Cas yana sake fasalin yanayin gyaran kwayoyin halitta a binciken likitanci. Wannan labarin ya binciki aikace-aikacensa, yana nuna babban yuwuwar magance cututtukan kwayoyin halitta, ciwon daji, da cututtuka masu yaduwa.
Sabuwar Hayar Rayuwa: Nasarar CD7 CAR-T Therapy Bridges don dashen ga yaro ɗan shekara 15 tare da T-ALL da ya koma baya
Wani lamari mai ban mamaki a BIOOCUS ya nuna tasirin maganin CD7 CAR-T ga wani yaro ɗan shekara 15 da ke fama da cutar sankarar lymphoblastic mai saurin kamuwa da cutar T-cell (T-ALL), wanda ke haifar da cikakkiyar gafara da kuma nasarar dashen na biyu.
Bioocus Ya Shiga Cikin IGC 2024 Don Binciken Sabbin Hadin Gwiwa Da Tsarin Kasuwanci A Tsarin Immuno-Gene Da Maganin Kwayoyin Halitta
Bioocus yana farin cikin shiga taron Immuno-Gene and Cell Therapy karo na 8 (IGC 2024)! Muna fatan yin aiki tare da kwararru na duniya da kuma binciko sabbin samfuran kasuwanci waɗanda suka dace da fasahar zamani ta maganin kwayoyin halitta da ƙwayoyin halitta. Tare, bari mu tsara makomar maganin rigakafi.
Gudanar da Illolin Maganin CAR-T Cell: Manyan Bayani daga Binciken Kwanan Nan
Wannan labarin labarai ya yi nuni da binciken da aka yi kwanan nan kan yadda ake sarrafa gubar maganin ƙwayoyin CAR-T ga ƙwayoyin B-cell lymphomas. Binciken ya jaddada dabarun magance illolin da aka saba gani kamar su cytokine release syndrome (CRS) da neurotoxicity (ICANS), tare da tabbatar da amfani da wannan magani mai ban mamaki cikin aminci.
Ingancin Maganin CD7 CAR-T ga Cututtukan B-Cell: Nasara a Maganin Ciwon Daji
Binciken da aka yi kwanan nan ya nuna inganci da amincin maganin ƙwayoyin CD7 CAR-T wajen magance cutar sankarar jini mai saurin kamuwa da cutar B-cell lymphoblastic leukemia (B-ALL) da kuma cutar sankarar lymphoblastic T-cell (T-LBL). Binciken da BIOOCUS ta gudanar tare da haɗin gwiwar Asibitin Lu Daopei, ya nuna sakamako mai kyau ga marasa lafiya, yana ba da madadin maganin chemotherapy na gargajiya.
Sabon Fata ga Ciwon Chemotherapy-B-Cell Lymphoma Mai Rage Ragewa: Maganin CAR-T Ya Nuna Sakamako Mai Kyau
Binciken, wanda aka buga a cikin Mujallar Ciwon Kankara ta Asibiti, yana nuna yawan sassaucin da ake samu ga marasa lafiya waɗanda suka gaji da zaɓuɓɓukan magani na gargajiya, wanda hakan ke nuna ci gaba mai kyau a fannin maganin cutar kansa.
Sakamako Mai Kyau Na Maganin CD7 CAR-T Da Aka Haɗa Da Dashen Jiki Na Biyu Ga Marasa Lafiyar T-ALL/LBL Da Suka Lalace
Wani bincike da aka yi kwanan nan ya nuna ingancin maganin CD7 CAR-T, sannan kuma a yi dashen ƙwayoyin halitta na allogeneic hematopoietic na biyu (HSCT) ga marasa lafiya da suka sake kamuwa da cutar T-cell acute lymphoblastic leukemia (T-ALL) da kuma lymphoblastic lymphoma (LBL), wanda hakan ya nuna babban yuwuwar cimma ƙarancin sassaucin rashin lafiya (MRD) - cikakkiyar waraka.
Ingancin Dogon Lokaci na Maganin Kwayoyin CAR na CD19 wajen Magance Cutar Leukemia Mai Lalacewa/Rage Ragewa
Wani bincike mai zurfi ya nuna nasarar da aka samu na dogon lokaci na maganin ƙwayoyin T-cell na CD19 CAR wajen magance marasa lafiya da suka sake kamuwa da cutar sankarar lymphoblastic mai tsanani (ALL) bayan dashen ƙwayoyin halitta na allogeneic, wanda hakan ke ba da sabon bege a fannin ilimin jini.
Bioocus Ya Ci Gaba Da Yaƙi Wajen Magance Ciwon Leukemia Mai Tsanani Na Yara
Bioocus yana kan gaba wajen haɓaka magungunan CAR-T na zamani. Littafin da Dr. Chunrong Tong da tawagarta suka buga kwanan nan a Asibitin Lu Daopei ya nuna muhimman ci gaba da ƙalubale wajen amfani da magungunan CAR-T na ƙarni na biyu na CD19 ga marasa lafiya na yara, wanda ke nuna jajircewar Bioocus ga maganin cutar kansa mai ƙirƙira.